Blue Corner Page Header

NxGen logo copy

A Disruptive Technology Enabling Transformative Medicine

Nanoparticle, Liposome, & Lipid Nanoparticle
Polymeric Nanoparticle & Liposome




NxGen simplifies and accelerates nanomedicine development by enabling all scales through one single mixing element.


NxGen achieves this unique scalability by preserving the critical, time-invariant conditions at the point of formulation regardless of whether the throughput is mL/min or L/hour.


The only technology that can scale a single mixer from mL/min to L/h.


Time-invariant particle formation to ensure the most reproducible results for a wide range of particle types.


This technology was developed exclusively by PNI

The Evolution of Microfluidic Nanomedicine Production

The proprietary NxGen microfluidic mixer at the heart of NanoAssemblr systems is designed specifically for nanomedicine development. Our Classic (formerly know as SHM) mixer was developed to address issues of reproducibility with scale up achieved by scale-out of parallel mixers.  NxGen however, is uniquely capable of > 25x throughput of our Classic mixer while maintaining the signature time-invariant particle formation conditions that ensure the most reproducible results for a wide range of particle types.

The Evolution of NxGen

The NxGen mixer enables the reproducible scale-up of mRNA-LNP and other complex nanomedicine formulations

  • Test batches of up to 20 L/h produced with a single NxGen mixer
  • Particle characteristics (size and PDI) are constant
  • Biological activity maintained

NxGen Microfluidic Technology Powering Genetic Medicine

NxGen Mixer Manufactures Equivalent mRNA-LNP when Compared to the Classic Mixer





Flow Rate






Encap. (%)


In vivo performance of mRNA-LNPs were equivalent when made with Classic or NxGen


Further Details

LNPs loaded with luciferase mRNA were formulated using Classic or NxGen Mixers. Mice were injected IV with one of 3 doses and 6 hrs later, were injected IP with luciferin. Mice were imaged for bioluminescence as a reporter for gene expression. Significance (p<0.05) determined by unparied t-test.

Challenging Formulation Scaled Up Through NxGen NanoAssemblr Platform
NxGen preserves manufacturing conditions through all stages of development while increasing throughput with a single mixer.

Size and PDI of POPC/Chol Liposomes Maintained Across NanoAssemblr Platform

NxGen Across Platform

Develop a Diverse Range of Formulations

Polymer nanoparticles, liposomes and nucleic acid lipid nanoparticles (LNPs) can be optimized.


For example:

(A) PLGA nanoparticles were optimized by systematically varying the initial polymer concentration. PLGA was dissolved in acetonitrile and mixed at a Flow Rate Ratio of 1:1 with water containing 2% PVA. 

(B) Liposome formulations were optimized by systematically varying the Flow Rate Ratio. Lipids were dissolved in ethanol and mixed at different Flow Rate Ratios with PBS buffer. 


Statistically equivalent results were obtained between Classic and NxGen configurations at the bench scale.

NP, Liposome, LNP, Polymer NP, Emulsion

A) Optimize Polymer Nanoparticle Formulations

Tune Polymer Nanoparticles

B) Optimize Liposome Formulations


NxGen Technology Throughout NanoAssemblr Platform

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch
Advanced Technology for
Advanced Nanomedicines
NxGen technology preserves non-turbulent mixing conditions to provide unparalleled control over nanoparticle assembly that is scalable from discovery to the clinic.


An aqueous phase and a miscible solvent containing dissolved nanoparticle precursors are injected into each inlet of the NanoAssemblr cartridge


Under laminar flow, the two phases do not immediately mix


Microscopic features engineered into the channel reproducibly control the mixing of the two streams


Rapid, controlled, homogenous mixing produces homogeneous nanoparticles
NanoAssemblr Technology
Placeholder brochure
NanoAssemblr Spark BrochureThe NanoAssemblr Spark has an operating nanoparticle formulation volume of 25 – 250 μL. By ensuring yields nearing 100%, the Spark is ideal for target validation screening and nanoparticle formulation development that involves scarce or expensive nucleic acid constructs and nanoparticle excipients.

Download Brochure

Resource Center

Publication - Summary

April 04, 2019

The Journal of Neuroscience

PTCD1 is Required for Mitochondrial Oxidative-phosphorylation: Possible Genetic Association with Alzheimer's Disease

D. Fleck, L. Phu, E. Verschueren, T. Hinkle, M. Reichelt, T. Bhangale, B. Haley, Y. Wang, R. Graham, D.S. Kirkpatrick, M...

Read More 阅读更多

Application Note

January 16, 2019

mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials

Read More 阅读更多 PDF

Publication - Abstract

November 01, 2018


Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies

B. Dejanovic, M.A. Huntley, A. De Mazière, W.J. Meilandt, T. Wu, K. Srinivasan and M. Sheng et al.

Read More 阅读更多


July 01, 2018

Robust low-volume production of nanoparticles for genetic manipulation of cells

Read More 阅读更多 PDF

Publication - Abstract

May 25, 2018

Multiple Myeloma

Microfluidic Production and Application of Lipid Nanoparticles for Nucleic Acid Transfection

A. Thomas, S.M. Garg, R.A.G. De Souza, E. Ouellet, G. Tharmarajah, D. Reichert, M. Ordobadi, S. Ip and E.C. Ramsay

Read More 阅读更多


December 04, 2017

Lipid Nanoparticles Deliver Nucleic Acids, Including CRISPR Components, in Primary Neurons

Read More 阅读更多 PDF
Resource Center 资源中心